Phase I single-group study (n=10) assessing neuroanatomical effects of intravenous ketamine in patients with treatment-resistant depression using pre- and post-treatment fMRI and perfusion measures.
This prospective Phase I study will evaluate durable neuroanatomical changes after clinician-prescribed intravenous ketamine in patients with treatment-resistant depression using structural T1, arterial spin labelling (ASL) and resting BOLD fMRI acquired one week before and two days after treatment.
Up to 10 patients meeting criteria for treatment-resistant depression will be enrolled. Ketamine will be injected per treating physician to achieve a dissociative state (dose individualised, reported range 75–1000 mg). Clinical measures include Beck Depression Inventory, Beck Anxiety Inventory and Brief Pain Inventory; imaging analyses will assess perfusion, neurovascular coupling and functional connectivity.
Single-group prospective evaluation of intravenous ketamine in treatment-resistant depression with pre- and post-treatment neuroimaging.
Dose individualised per clinician to achieve dissociative state (75–1000 mg).